221 related articles for article (PubMed ID: 11725974)
1. Plasma, intestine and tumor levels of 5-fluorouracil in mice bearing L1210 ascites tumor following oral administration of 5-fluorouracil, UFT (mixed compound of tegafur and uracil), carmofur and 5'-deoxy-5-fluorouridine.
Ooi A; Ohkubo T; Higashigawa M; Kawasaki H; Kakito H; Kagawa Y; Kojima M; Sakurai M
Biol Pharm Bull; 2001 Nov; 24(11):1329-31. PubMed ID: 11725974
[TBL] [Abstract][Full Text] [Related]
2. Effects of UFT (mixed compound of tegafur and uracil) on cell kinetics and inhibition of thymidylate synthase in L1210 ascites tumor.
Kagawa Y; Ohkubo T; Higashigawa M; Ido M; Kakito H; Inagaki S; Kojima M; Ooi K; Sakurai M
Cancer Invest; 1995; 13(5):470-4. PubMed ID: 7552812
[TBL] [Abstract][Full Text] [Related]
3. Effects of 5-fluorouracil and a combination of tegafur and uracil (UFT) on nucleotide metabolism in L1210 ascites tumor.
Kakito H; Ohkubo T; Kagawa Y; Inagaki S; Sumida K; Ooi K; Higashigawa M; Sakurai M
Cancer Invest; 1993; 11(5):530-3. PubMed ID: 8402222
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic effects of orally administered 5'-deoxy-5-fluorouridine, 1-(2-tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil on experimental murine tumors.
Uehara N; Baba H; Nitta K; Kunimoto T; Takeuchi M; Sasaki T; Tanaka T
Jpn J Cancer Res; 1985 Oct; 76(10):1034-41. PubMed ID: 2934356
[TBL] [Abstract][Full Text] [Related]
5. [Chemotherapy with fluoropyrimidines for MOPC-104E plasmacytoma transplanted in mice with CCl4 induced chronic liver dysfunction].
Tsubono M; Nio Y; Imai S; Shiraishi T; Morimoto H; Tseng CC; Tobe T
Nihon Gan Chiryo Gakkai Shi; 1990 Mar; 25(3):640-7. PubMed ID: 2141051
[TBL] [Abstract][Full Text] [Related]
6. Randomized controlled trial of the efficacy of adjuvant immunochemotherapy and adjuvant chemotherapy for colorectal cancer, using different combinations of the intracutaneous streptococcal preparation OK-432 and the oral pyrimidines 1-hexylcarbamoyl-5-fluorouracil and uracil/tegafur.
Watanabe M; Nishida O; Kunii Y; Kodaira S; Takahashi T; Tominaga T; Hojyo K; Kato T; Niimoto M; Kunitomo K; Isomoto H; Ohashi Y; Yasutomi M
Int J Clin Oncol; 2004 Apr; 9(2):98-106. PubMed ID: 15108041
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil.
Muggia FM; Wu X; Spicer D; Groshen S; Jeffers S; Leichman CG; Leichman L; Chan KK
Clin Cancer Res; 1996 Sep; 2(9):1461-7. PubMed ID: 9816321
[TBL] [Abstract][Full Text] [Related]
8. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats.
Takechi T; Nakano K; Uchida J; Mita A; Toko K; Takeda S; Unemi N; Shirasaka T
Cancer Chemother Pharmacol; 1997; 39(3):205-11. PubMed ID: 8996521
[TBL] [Abstract][Full Text] [Related]
10. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
Hoff PM; Pazdur R; Benner SE; Canetta R
Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of pharmacokinetics of 5-FU and alpha-fluoro-beta-alanine, a metabolite of 5-FU, in plasma after administration of UFT, tegafur, 5-FU or doxifluridine to rats].
Kuwata K; Nagayama S; Hirakawa Y; Matsushima E; Kawaguchi Y
Gan To Kagaku Ryoho; 2000 Jun; 27(6):885-90. PubMed ID: 10897216
[TBL] [Abstract][Full Text] [Related]
12. [5-FU concentrations in the blood and tumor tissue after 5'-DFUR or UFT administration in the patients with uterine cervical cancer].
Suzuki M; Aida I; Ohwada M; Sato I; Tamura T; Kasuga Y
Gan To Kagaku Ryoho; 1995 Feb; 22(2):253-8. PubMed ID: 7857101
[TBL] [Abstract][Full Text] [Related]
13. 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil.
Cao S; Baccanari DP; Joyner SS; Davis ST; Rustum YM; Spector T
Cancer Res; 1995 Dec; 55(24):6227-30. PubMed ID: 8521418
[TBL] [Abstract][Full Text] [Related]
14. Studies on the metabolism of 1-(2-tetrahydrofuryl)-5-fluorouracil and uracil co-administered orally to tumor-bearing rats.
Kawaguchi Y; Nagayama S; Masuda H; Yasuda A
Gan; 1980 Dec; 71(6):889-99. PubMed ID: 6791982
[TBL] [Abstract][Full Text] [Related]
15. UFT is more antineoplastic against gastric carcinoma than 5-fluorouracil, 1-(2-tetrahydrofuryl)-5-fluorouracil and 1-hexylcarbamoyl-5-fluorouracil.
Maehara Y; Kusumoto T; Kusumoto H; Anai H; Sugimachi K
Chemotherapy; 1988; 34(6):484-9. PubMed ID: 3149571
[TBL] [Abstract][Full Text] [Related]
16. [Chemosensitivity of head and neck squamous cell carcinomas using subrenal capsule assay--comparative assay of 5-FU, FT, UFT, and HCFU and immunohistochemical study].
Nakashima T; Miyagi M; Kusumoto T
Nihon Jibiinkoka Gakkai Kaiho; 1992 Jan; 95(1):95-103. PubMed ID: 1545316
[TBL] [Abstract][Full Text] [Related]
17. [Study on the concentrations of 5-fluorouracil (5-FU), tegafur (ET) and uracil in bile: comparison of UFT or FT].
Tomita T; Tajima T; Ishibashi M; Tagaya N; Aoki H; Itoh S; Kadowaki A; Kogure H; Tajima Y
Gan To Kagaku Ryoho; 1989 Dec; 16(12):3755-62. PubMed ID: 2512859
[TBL] [Abstract][Full Text] [Related]
18. A pharmacological study of the weekday-on/weekend-off oral UFT schedule in colorectal cancer patients.
Sadahiro S; Suzuki T; Kameya T; Iwase H; Tajima T; Makuuchi H
Cancer Chemother Pharmacol; 2001 May; 47(5):457-60. PubMed ID: 11391863
[TBL] [Abstract][Full Text] [Related]
19. [Effects of derivatives of Ara-C, 5-fluorouracil and nitrosourea against intracerebral implanted L1210 leukemia].
Kato T; Ota K
Gan To Kagaku Ryoho; 1987 Feb; 14(2):502-5. PubMed ID: 2949703
[TBL] [Abstract][Full Text] [Related]
20. Clinical basis of chemotherapy for gastric cancer with uracil and 1-(2'-tetrahydrofuryl)-5-fluorouracil.
Kimura K; Suga S; Shimaji T; Kitamura M; Kubo K; Suzuoki Y; Isobe K
Gastroenterol Jpn; 1980; 15(4):324-9. PubMed ID: 6773844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
